bromocriptine has been researched along with pramipexole in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (29.73) | 18.2507 |
| 2000's | 19 (51.35) | 29.6817 |
| 2010's | 6 (16.22) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Griffon, N; Lévesque, D; Pilon, C; Sautel, F; Schwartz, JC; Sokoloff, P | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hoffmann, WE; Hyslop, DK; Piercey, MF; Smith, MW | 1 |
| Fici, GJ; Sethy, VH; VonVoigtlander, PF; Wu, H | 1 |
| Hall, ED; Oostveen, JA; Sethy, VH; Wu, H | 1 |
| Kitamura, Y; Kohno, Y; Nakazawa, M; Nomura, Y | 1 |
| Wienkers, LC; Wynalda, MA | 1 |
| Guttman, M | 1 |
| Kakimura, JI; Kitamura, Y; Kohno, Y; Kosaka, T; Matsuoka, Y; Nomura, Y; Taniguchi, T | 1 |
| Factor, SA | 1 |
| Weiner, WJ | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Clarke C, E; Clarke J, A; Speller J, M | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Jankovic, J; Le, WD | 1 |
| Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, S; Moramarco, A; Palagano, G; Zenzola, A | 1 |
| Gekht, AB | 1 |
| Blackman, JA; Buck, ML; Conaway, MR; Patrick, PD | 1 |
| Bankowski, BJ; Zacur, HA | 1 |
| Hasegawa, K; Kowa, H; Kuno, S; Mizuno, Y; Origasa, H; Yamamoto, M; Yanagisawa, N | 1 |
| Lang, AE; Razmy, A; Shapiro, CM | 1 |
| Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Daida, H; Hatano, T; Hattori, N; Iwama, Y; Komine-Kobayashi, M; Mizuno, Y; Mochizuki, H; Nakayama, T; Sakai, M; Urabe, T; Yamashiro, K | 1 |
| Akaike, A; Izumi, Y; Kume, T; Niidome, T; Oda, T; Takada-Takatori, Y | 1 |
| Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C | 1 |
| Andersohn, F; Garbe, E | 1 |
| Audebert, C; Blin, O; Eusebio, A; Jouve, E; Micallef, J; Rey, M; Rouby, F; Tardieu, S | 1 |
| Fujioka, S; Iwamoto, K; Kawamura, M; Nakajima, M; Ohno, H | 1 |
| Bottasini, V; Clemens, S; Ferini-Strambi, L; Ferri, R; Giarolli, L; Manconi, M; Zucconi, M | 1 |
| Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Dieb, W; Durif, F; Hafidi, A; Ouachikh, O | 1 |
| Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C | 1 |
| Chen, F; Chen, X; Wen, S; Zhang, Q; Zhou, C | 1 |
12 review(s) available for bromocriptine and pramipexole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dopamine agonists.
Topics: Apomorphine; Benzothiazoles; Bromocriptine; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Receptors, Dopamine; Thiazoles; Treatment Outcome | 1999 |
The initial treatment of Parkinson's disease should begin with levodopa.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Drug Therapy, Combination; Essential Tremor; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine; Thiazoles; Time Factors | 1999 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Tolerance; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles | 2000 |
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Bromocriptine; Cell Culture Techniques; Clinical Trials as Topic; Dopamine Agonists; Humans; Indoles; Models, Animal; Neuroprotective Agents; Parkinson Disease; Pergolide; Pramipexole; Substantia Nigra; Thiazoles | 2001 |
[Use of dopamine agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors | 2002 |
Dopamine agonist therapy for hyperprolactinemia.
Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles | 2003 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes | 2017 |
Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Network Meta-Analysis; Parkinson Disease; Pergolide; Pramipexole | 2023 |
6 trial(s) available for bromocriptine and pramipexole
| Article | Year |
|---|---|
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Pramipexole; Quality of Life; Severity of Illness Index; Thiazoles; Treatment Outcome | 1997 |
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Demography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Quality of Life; Thiazoles; Time Factors; Treatment Outcome | 2003 |
Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cross-Over Studies; Double-Blind Method; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Pramipexole; Sleep Wake Disorders; Treatment Outcome; Young Adult | 2009 |
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Humans; Japan; Outcome Assessment, Health Care; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.
Topics: Adult; Aged; Analysis of Variance; Benzothiazoles; Bromocriptine; Cross-Over Studies; Electromyography; Female; Humans; Leg; Male; Middle Aged; Movement; Pain Measurement; Polysomnography; Pramipexole; Prospective Studies; Receptors, Dopamine D2; Receptors, Dopamine D3; Restless Legs Syndrome; Single-Blind Method; Statistics, Nonparametric | 2011 |
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2013 |
19 other study(ies) available for bromocriptine and pramipexole
| Article | Year |
|---|---|
A functional test identifies dopamine agonists selective for D3 versus D2 receptors.
Topics: Animals; CHO Cells; Cricetinae; Dopamine Agents; Humans; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3 | 1995 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Bromocriptine; CHO Cells; Cricetinae; Dopamine Agonists; Dose-Response Relationship, Drug; Male; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Substantia Nigra; Thiazoles | 1996 |
D1 dopamine receptor activity of anti-parkinsonian drugs.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Benzothiazoles; Bromocriptine; Cells, Cultured; Cerebellum; Clozapine; Cyclic AMP; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiazoles | 1997 |
Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats.
Topics: Adenosine Triphosphate; Animals; Benzothiazoles; Body Temperature; Bromocriptine; Cerebellum; Cyclic GMP; Dopamine Agonists; Male; Motor Activity; Neurons; Neuroprotective Agents; Neurotoxins; Olivary Nucleus; Pramipexole; Pyridines; Rats; Rats, Wistar; Thiazoles | 1997 |
Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Azepines; Benzothiazoles; Bromocriptine; Dopamine; Dopamine Agents; Dopamine Agonists; Homovanillic Acid; In Vitro Techniques; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Neostriatum; Pramipexole; Synaptosomes; Thiazoles | 1997 |
Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen.
Topics: Benzothiazoles; Bromocriptine; Cytochrome P-450 Enzyme Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Humans; Indoles; Pergolide; Pramipexole; Thiazoles | 1997 |
Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.
Topics: 1-Methyl-4-phenylpyridinium; Antiparkinson Agents; Apoptosis; Azepines; Benzothiazoles; Bromocriptine; Bucladesine; Caspase 3; Caspases; Dopamine Agonists; Humans; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Thiazoles; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
Efficacy and tolerability of dopamine agonists in a parkinsonian population.
Topics: Age of Onset; Aged; Aging; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Ergolines; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome | 2001 |
The use of dopamine enhancing medications with children in low response states following brain injury.
Topics: Adolescent; Adult; Amantadine; Arousal; Awareness; Benzothiazoles; Brain Injuries; Bromocriptine; Child; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Methylphenidate; Neuropsychological Tests; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome; Unconsciousness | 2003 |
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Topics: Aged; Benzothiazoles; Bromocriptine; Disorders of Excessive Somnolence; Dopamine Agonists; Dose-Response Relationship, Drug; Ergot Alkaloids; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pergolide; Polysomnography; Pramipexole; Prospective Studies; Sleep; Thiazoles; Wakefulness | 2004 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
The frequency of cardiac valvular regurgitation in Parkinson's disease.
Topics: Aged; Aortic Valve Insufficiency; Azepines; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Prevalence | 2008 |
Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
Topics: Animals; Azepines; Benzothiazoles; Blotting, Western; Bromocriptine; Dopamine Agonists; Dose-Response Relationship, Drug; Ergonovine; Ergot Alkaloids; Methylergonovine; Mitogen-Activated Protein Kinases; Neurites; PC12 Cells; Pramipexole; Rats; Receptors, Dopamine D2 | 2008 |
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors | 2009 |
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States | 2009 |
Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats.
Topics: Animals; Benzothiazoles; Bromocriptine; Cocaine; Conditioning, Psychological; Dopamine Agonists; Dopaminergic Neurons; Male; Motivation; Motor Activity; Pramipexole; Rats; Rats, Sprague-Dawley; Ventral Tegmental Area | 2014 |